Role of Hematological Parameters in the Stratification of COVID-19 Disease Severity

Completed

• Conditions: Covid19
• Interventions: Diagnostic Test: not required

• Registration Number: NCT04670328
• Lead Sponsor: FMH College of Medicine and Dentistry

Brief Summary

The hemostatic abnormalities in COVID-19 are related with disease progression, severity and mortality. The Objective of our study is to evaluate the role of hematological parameters in determination of COVID-19 disease severity.

Detailed Description

Objective:

COVID-19 virus involves respiratory as well as other body systems including cardiovascular, gastrointestinal, neurological, immunological and hematopoietic system. Patient of covid-19 pneumonia presents with wide range of hemostatic abnormalities. These hemostatic abnormalities in COVID-19 are related with disease progression, severity and mortality. The Objective of our study is to evaluate the role of hematological parameters in determination of COVID-19 disease severity.

Material and Method:

This was a retrospective study, conducted in Department of Pathology and Department of medicine, FMH college of Medicine and Dentistry from May 2020 to July 2020. Total of 101, confirmed cases of covid-19 disease, both genders between 17 to 75-year age were included. Hematological parameters were compared in mild, moderate, severe and critical disease group. Continuous variables were analyzed by using non parametric, Kruskal Wallis test while categorical variables were analyzed by chi-square test.

Study Timeline

• Study Start: 2020-05-01
• Primary Completion: 2020-07-31
• Study Completion: 2020-07-31
• Status Verified: 2020-12
• Study First Submitted: 2020-12-14
• Study First Submitted QC: 2020-12-15
• Last Update Submitted: 2020-12-15
• Study First Posted: 2020-12-17
• Last Update Posted: 2020-12-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 101

Inclusion Criteria

• diagnosed cases of covid-19 disease
• Both genders
• 17 to 75 year age

Exclusion Criteria

• known case of chronic liver disease
• known hematological diseases were excluded

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Covid-19 disease severity	not required	Mild, moderate, severe and critical disease

Primary Outcome Measures

Name	Time	Method
complete blood count- Hemoglobin. White blood count, platelet count, Neutrophil to lymphocyte ratio	3 months	disease severity was assessed on basis of hematological parameters.

Secondary Outcome Measures

Name	Time	Method
PT, APTT and D-dimer	3 months	improvement in PT, APTT and D-dimer levels were assessed

Trial Locations

Locations (1)

FMH college of medicine and dentistry; 🇵🇰 Lahore, Punjab, Pakistan